News

One date in the next decade is quietly doing all the work in Wall Street’s newest bear case.

Morgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook

The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.

Investing.com -- Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell from Hold and cut its price target by 9% to 265 Danish crowns from 290 crowns, flagging persisting concerns over the company’s growth trajectory. The stock fell more than 3% in Copenhagen trading Thursday.

By Tharuniyaa Lakshmi and Utkarsh Hathi Aug 25 (Reuters) - European shares rose on Tuesday as investors took comfort from a softer-than-feared U.S. sanctions package on Iran and falling oil prices,

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications.

Investing.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) hiked its full-year guidance, saying annual sales and operating profit should decline less than previously expected as demand for its weight-loss drugs continues unabated.

Novo now expects underlying sales and operating profit in the range of 0% to –6% for the year.

U.S.-traded shares of Novo Nordisk are down more than 6% due to a sales shortfall for its new Wegovy weight-loss pill and a disappointing study outcome for a next-generation weight-loss drug. Overall, the company sees the potential for a full-year sales decline of up to 6%, better than its previous view that sales could drop up to 12%. Novo also disclosed that its experimental drug CagriSema failed to show comparable blood-sugar reduction to Eli Lilly’s tirzepatide in a new study of people with Type 2 diabetes.

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

Novo Nordisk shares dropped after the Danish drugmaker said an experimental medicine didn't reduce risk of major adverse cardiovascular events in a late-stage trial. The company's Denmark-listed stock was down nearly 10%, while its American depositary receipts fell about 9% in premarket trading in New York.

Investing.com -- Novo Nordisk (NYSE: NVO) shares dropped 10% Friday after the drugmaker revealed its experimental drug, ziltivekimab, failed to cut cardiovascular risk in a late-stage clinical trial.

The stock was down 9.5% after the company’s experimental medicine ziltivekimab didn’t achieve the expected risk reduction for major cardiovascular events.

The telehealth provider shared patient health information with Snap and Meta, a federal complaint says.

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Novo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.

European stock markets fell in late Tuesday trading as oil prices rose after negotiations between th

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr

By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift